Cell Line News and Research

RSS

Novel platform can become a potential approach for personalized cancer treatments

Killing cancer cells without affecting surrounding normal cells is the most desirable approach for targeted cancer therapy. However, it cannot be easily achieved due to the similarities in the properties between normal and cancer cells.

22 Feb 2022

Surfactant-containing oral mouthwashes target the lipid envelope of SARS-CoV-2

Researchers demonstrated the composition and importance of SARS-CoV-2 lipid envelope and assessed the antiviral potential of oral mouthwashes targeting these lipid envelopes.

21 Feb 2022

Study reports a highly attenuated SARS-CoV-2 that could serve as a live-attenuated vaccine platform

The research showed a highly attenuated SARS-CoV-2 strain that might be used as a live-attenuated vaccine platform and a BSL-2 experimental system.

18 Feb 2022

Antiviral potential of N-acylethanolamine acid amide hydrolase against SARS-CoV-2 and Zika virus

A recent study posted to the bioRxiv* pre-print server investigated the antiviral potential of N-acylethanolamine acid amidase (NAAA) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the Zika virus (ZIKV).

14 Feb 2022

Study shows expression of viral proteases may be used to quantitate SARS-CoV-2 infected cells

A new study describes a new method to quantify SARS-CoV-2 infection, which is much simpler and faster compared to existing methods.

14 Feb 2022

Nitazoxanide shows promise for COVID-19 treatment in animal model

In a recent study posted to the bioRxiv* pre-print server, researchers demonstrated that Nitazoxanide (NTZ), an oral drug, broadly inhibits replication of several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) in preclinical models of infection.

13 Feb 2022

Study explores inflammation of endothelial cells by exosomes from COVID-19 patients

In a new study, researchers revealed that the nucleotide-binding oligomerization domain-like receptors or NOD-like receptors family pyrin domain containing 3 (NLRP3) inflammasome is activated by the exosomes from plasma in COVID-19.

9 Feb 2022

Antarctic soil sample from 2018 adds to the enigma of the COVID-19 pandemic

The origin of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has long been debated among scientists. However, prior research found early genetic material of a unique SARS-CoV-2 variant from the soil on King George Island, Antarctica between 24 December 2018 and 13th January 2019.

9 Feb 2022

Potential tumor vulnerability may be exploited to improve treatment of neuroblastoma

A Ludwig Cancer Research study has identified a potential vulnerability in neuroblastoma tumors that might be exploited to improve treatment of the aggressive childhood cancer, which accounts for roughly 15% of all deaths from pediatric malignancies.

7 Feb 2022

USP22 crucial for type III interferon signaling and SARS-CoV-2 infection

In a recent study posted to the bioRxiv* pre-print server, a team of researchers demonstrated that ubiquitin-specific peptidase 22 (USP22) is a crucial regulator of basal interferon (IFN) signaling in native human intestinal epithelial cells (hIECs).

7 Feb 2022

SARS-CoV-2 entry at the cell surface facilitated by trypsin

Exogenous trypsin treatment boosts SARS-CoV-2 infection in Vero E6 cells and promotes viral multiplication in cultured cells.

1 Feb 2022

Vaccine-induced immunological memory is similar for Omicron and Delta SARS-CoV-2 variants

A new study by Norwegian researchers suggests that vaccine-induced immunological memory and the activation of recall responses in the body yields similar coverage for Omicron and Delta variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The paper is currently available on the medRxiv* preprint server while it undergoes peer review.

31 Jan 2022

Research opens up new avenues for cancer treatment

Researchers at Koç University discovered why a promising class of cancer treatments fail, and their findings point to how such treatments might be made to work.

28 Jan 2022

Potential therapy candidates for patients infected with the SARS-CoV-2 Omicron variant

Researcher discusses several promising therapeutic candidates that have been proposed for the treatment of patients infected with the Omicron variant.

28 Jan 2022

Targeting SARS-CoV-2 M protein may help ease severity of COVID-19

A new study, published on the medRxiv preprint server, focused on the production of human CD4+ T cell lines (TCLs), reactive to either S or M protein, and analyzed if the S and M structural proteins had intrinsic differences in driving antigen-specific CD4+ T cell responses.

27 Jan 2022

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

A new study assesses SARS-CoV-2 antigen-specific cytokine responses in a cohort of SARS-CoV-2 infected individuals with varying levels of disease.

26 Jan 2022

Endosomal sorting of neuropilin-1 in SARS-CoV-2 infectivity

A study recently identified Neurolipin-1 or NRP1, a host factor for SARS-CoV-2 infection, as a cargo retrograde-transported by the ESCPE-1.

26 Jan 2022

SARS-CoV-2 virus co-opts intrinsic cellular machinery to suppress interferon production

In a recent study posted to the bioRxiv* preprint server, researchers evaluated the mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated inflammatory marker interferon (IFN) repression in hosts.

25 Jan 2022

PAXLOVID shown to be highly effective against all SARS-CoV-2 variants

A recent study, currently available on bioRxiv* preprint server, shows that a novel protease inhibitor known as nirmatrelvir has potent activity against Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but also other variants evaluated in this paper – which supports its potential role in reducing the disease burden from coronavirus disease 2019 (COVID-19).

21 Jan 2022

Study finds Omicron infection effectively induces immunity against itself and enhances protection against other variants in vaccinated individuals

Researchers investigated the effectiveness of the SARS-CoV-2 Omicron-variant induced immunity, whether it is cross-protective against other variants, and if earlier infection with the SARS-CoV-2 Delta variant offers protection against Omicron.

20 Jan 2022